Advanced search
Publication Cover
Cancer Investigation Volume 31, 2013 - Issue 3
Submit an article Journal homepage
334
Views
14
CrossRef citations to date
0
Altmetric
CLINICAL TRANSLATIONAL RESEARCH

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Lauren A. HeldDivision of Cellular Therapy
,
David RizzieriDivision of Cellular Therapy
,
Gwynn D. LongDivision of Cellular Therapy
,
Jon P. Gockermanand Divisions of Oncology and Hematology Duke University Medical Center, Durham, North Carolina, USA
,
Louis F. Diehland Divisions of Oncology and Hematology Duke University Medical Center, Durham, North Carolina, USA
,
Carlos M. de Castroand Divisions of Oncology and Hematology Duke University Medical Center, Durham, North Carolina, USA
,
Joseph O. Mooreand Divisions of Oncology and Hematology Duke University Medical Center, Durham, North Carolina, USA
,
Mitchell E. HorwitzDivision of Cellular Therapy
,
Nelson J. ChaoDivision of Cellular Therapy
&
Cristina GasparettoDivision of Cellular TherapyCorrespondence[email protected]
 show all
Pages 172-176 | Received 20 Jul 2012, Accepted 25 Nov 2012, Published online: 13 Feb 2013

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Xin Li & Wan-Jun Sun. (2015) The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma. OncoTargets and Therapy 8, pages 775-781.
Read now
Xuepeng He, Kai Yang, Peng Chen, Bing Liu, Yuan Zhang, Fang Wang, Zhi Guo, Xiaodong Liu, Jinxing Lou & Huiren Chen. (2014) Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. OncoTargets and Therapy 7, pages 1593-1599.
Read now

Articles from other publishers (12)

Ali Zahit Bolaman, Atakan Turgutkaya, Hilal Eroğlu Küçükdiler, Cem Selim & İrfan Yavaşoğlu. (2021) Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients. Leukemia Research Reports 16, pages 100281.
Crossref
Malgorzata Firczuk, Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Klaudyna Fidyt, Agnieszka Goral & Radoslaw Zagozdzon. (2020) Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy. Cancer Letters 471, pages 1-11.
Crossref
Gina Nauman, Javaughn Gray, Rose Parkinson, Mark Levine & Channing Paller. (2018) Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. Antioxidants 7:7, pages 89.
Crossref
Kevin Barley & Samir Parekh. 2018. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas 45 71 .
Danka Cholujova, Zdenka Bujnakova, Erika Dutkova, Teru Hideshima, Richard W. Groen, Constantine S. Mitsiades, Paul G. Richardson, David M. Dorfman, Peter Balaz, Kenneth C. Anderson & Jana Jakubikova. (2017) Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma . British Journal of Haematology 179:5, pages 756-771.
Crossref
Jiliang Xia, Hongwei Xu, Xiaoyan Zhang, Chantal Allamargot, Kristen L. Coleman, Randy Nessler, Ivana Frech, Guido Tricot & Fenghuang Zhan. (2017) Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. EBioMedicine 18, pages 41-49.
Crossref
Hebing Zhou, Jinqing Li, Yuan Jian, Tingting Chen, Haiteng Deng, Juan Zhang, Hui Zeng, Zhijuan Shan & Wenming Chen. (2016) Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. Experimental Hematology 44:2, pages 125-131.e11.
Crossref
Hye Ji ChoiTae-Hee KimSoo Ah KimJun-Mo KimArum LeeHyeon Jin SongYoo Jin Park. (2016) Cell Therapy Products in Menopausal Medicine. Journal of Menopausal Medicine 22:2, pages 71.
Crossref
XIAONING WANG & MEI ZHANG. (2015) Synergistic effects of valproic acid and arsenic trioxide on RPMI8226 cells in vitro and the possible underlying mechanisms. Molecular Medicine Reports 12:1, pages 1449-1456.
Crossref
GIOU-TENG YIANG, PEI-LUN CHOU, YU-TING HUNG, JEN-NI CHEN, WEI-JUNG CHANG, YUNG-LUEN YU & CHYOU-WEI WEI. (2014) Vitamin C enhances anticancer activity in methotrexate-treated Hep3B hepatocellular carcinoma cells. Oncology Reports 32:3, pages 1057-1063.
Crossref
Wen-Xiao Xu, Yang Liu, Sheng-Zhi Liu, Yu Zhang, Guo-Fen Qiao & Jinglong Yan. (2014) Arsenic trioxide exerts a double effect on osteoblast growth in vitro. Environmental Toxicology and Pharmacology 38:2, pages 412-419.
Crossref
Michael J. Gonzalez & Jorge R. Miranda-MassariMichael J. Gonzalez & Jorge R. Miranda-Massari. 2014. New Insights on Vitamin C and Cancer. New Insights on Vitamin C and Cancer 27 55 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.